RecruitingPhase 2Drug trialAnti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)This is a phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain metastases.